Sector View

Nomura's latest sector report presents a positive outlook for Indian pharmaceuticals, highlighting momentum driven by chronic therapies and the nascent GLP-1 drug market. However, beneath the optimistic tone lies a more complex reality. The market's reliance on price increases rather than unit sales, coupled with intense competition in high-growth segments, suggests a challenging path for sustained, broad-based growth.

The Valuation Gap

Nomura's positive view has boosted sentiment, but current market valuations are mixed. Nomura's top pick, Cipla, has a P/E of about 21.52, significantly lower than Sun Pharmaceutical Industries' P/E of around 36.37. Dr. Reddy's Laboratories has a P/E of roughly 18.52, appearing more attractive than some peers. Torrent Pharmaceuticals trades at a much higher P/E of 62.25, suggesting high growth expectations or stretched valuations. Glenmark Pharmaceuticals also has a high P/E of about 58.30, raising questions about whether its growth is already priced in. This valuation gap highlights that while Nomura sees sector-wide opportunity, investor sentiment and expected growth vary significantly among individual companies.

Analytical Deep Dive

The sector's growth narrative relies more on price increases and new products than on higher sales volumes. In March 2026, the Indian Pharmaceutical Market (IPM) grew 10.1%, with volume contributing only 1.1% and pricing adding 5.5%. This reliance on price hikes is a recurring trend. A Goldman Sachs report noted similar patterns in Q3 FY25, where pricing increases offset negative volume growth. Looking ahead, ICRA forecasts 7-9% revenue growth for FY2026, driven by domestic and European markets. However, it cautions that US market growth may slow due to ongoing price erosion and regulatory scrutiny.

The emerging GLP-1 market, notably for Semaglutide, shows this intense competition. Following patent expiries, Indian players like Dr. Reddy's Laboratories, Zydus Lifesciences, and Glenmark Pharmaceuticals have launched generic versions. Glenmark has positioned its product at a weekly cost of Rs325-440, while Sun Pharma's offerings range from Rs750 to Rs2,000 weekly. This aggressive pricing, while improving access, signals rapid commoditization of a key therapeutic class, potentially squeezing margins for all players despite market share gains. Industry analysts anticipate India's GLP-1 market could multiply fivefold by 2030. Globally, emerging markets are projected to grow at nearly twice the global average, indicating a strategic shift for Indian players beyond traditional developed markets.

Key Challenges and Risks

Despite Nomura's optimistic view, structural challenges remain. The heavy reliance on price hikes for market growth, seen in the 1.1% volume rise in March 2026, creates fragility. If price increases become unsustainable or face regulatory capping, growth could falter. The GLP-1 market, seen as a major growth driver, is already facing an aggressive price war among Indian companies. This intense competition and rapid commoditization suggest that expected profit gains from this segment may be modest for most companies.

Global uncertainties, including geopolitical tensions and supply chain disruptions, also pose risks. Rising costs for APIs and intermediates, worsened by shipping route issues, could pressure margins in the short term. Companies like Glenmark Pharmaceuticals, despite strong growth metrics, trade at a high P/E over 58, potentially meaning much of its upside is priced in and leaving it vulnerable to slower growth.

Future Outlook

Nomura's report favors companies with strong pipelines and unique products, indicating a selective strategy for growth. Nomura's positive ratings for Dr. Reddy's and Zydus Lifesciences, due to their early moves in the GLP-1 market, align with this focus. However, the wider market outlook from ICRA projects 7-9% revenue growth for FY2026, driven by domestic and European markets. It warns of slower growth in the U.S. due to price erosion and regulatory issues. The Indian pharmaceutical market is projected to reach USD 79.74 billion by 2031, growing at a CAGR of 5.74%. This indicates a positive long-term trend, though shaped by intense competition and changing pricing dynamics.